JPH10511407A - 高用量難溶性薬物用持続放出マトリックス - Google Patents
高用量難溶性薬物用持続放出マトリックスInfo
- Publication number
- JPH10511407A JPH10511407A JP10505408A JP50540898A JPH10511407A JP H10511407 A JPH10511407 A JP H10511407A JP 10505408 A JP10505408 A JP 10505408A JP 50540898 A JP50540898 A JP 50540898A JP H10511407 A JPH10511407 A JP H10511407A
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- dosage form
- sustained release
- xanthan gum
- gum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.約500 mg〜約1000 mg の難溶性NSAIDおよび有効量の持続放出担体を含 む持続放出剤形であって、該剤形の放出により、USPII型(パドル)法によっ て測定すると該NSAIDの約6重量%が約2時間後に放出され、約12〜約16時 間後にt50となる該NSAIDのin vitroでの溶解を提供する剤形。 2.該持続放出担体がキサンタンガムおよび架橋剤を含む、請求項1に記載の剤 形。 3.該架橋剤がガラクトマンナンである、請求項2に記載の剤形。 4.該ガラクトマンナンがローカストビーンガムである、請求項3に記載の剤形 。 5.さらに不活性希釈剤を含む、請求項1に記載の剤形。 6.該NSAIDが、イブプロフェン、カルシウムフェノプロフェン、ナプロキ セン、エトドラック、メフェナム酸、トルメチンおよびそれらの混合物から成る 群から選択される、請求項1に記載の剤形。 7.該NSAIDがイブプロフェンである、請求項1に記載の剤形。 8.錠剤の形状である、請求項1に記載の剤形。 9.該架橋剤が、ガラクトマンナンガム、イオン化可能なゲル強度増強剤または それらの組み合わせを含む、請求項2に記載の剤形。 10.約500 mg〜約1000 mg の難溶性NSAIDおよび有効量の持続放出担体を 含む持続放出剤形であって、該剤形の放出により、USPII型(パドル)法によ って測定すると該イブプロフェンの約20重量%が約4時間後に放出され、約12〜 約16時間後にt50となる該NSAIDのin vitroでの溶解が得られる剤形。 11.該持続放出担体がキサンタンガムおよび架橋剤を含む、請求項10に記載 の剤形。 12.該架橋剤がガラクトマンナンである、請求項11に記載の剤形。 13.該ガラクトマンナンがローカストビーンガムである、請求項12に記載の 剤形。 14.さらに不活性希釈剤を含む、請求項11に記載の剤形。 15.該NSAIDが、イブプロフェン、カルシウムフェノプロフェン、ナプロ キセン、エトドラック、メフェナム酸、トルメチンおよびそれらの混合物から成 る群から選択される、請求項10に記載の剤形。 16.該NSAIDがイブプロフェンである、請求項10に記載の剤形。 17.該架橋剤が、ガラクトマンナンガム、イオン化可能なゲル強度増強剤また はそれらの組み合わせを含む、請求項12に記載の剤形。 18.約500 mg〜約1000 mg のイブプロフェン;疎水性物質を含む持続放出被覆 剤;およびキサンタンガムを含む錠剤コアを含む持続放出イブプロフェン剤形で あって、該イブプロフェンの約1〜約20重量%が該錠剤上に被覆され、該剤形の 放出により、USPII型(パドル)法によって測定すると該NSAIDの約6重 量%が約2時間後に放出され、約12〜約16時間後にt50となる該NSAIDのin vitroでの溶解が得られる剤形。 19.約500 mg〜約1000 mg のイブプロフェンならびに約5〜約95 %のキサンタ ンガムおよびローカストビーンガムを含む架橋剤を含む持続放出担体を含むマト リックスを含み、該キサンタンガムおよび該ローカストビーンガムの合計重量に 対する該イブプロフェンの重量比が約1:0.06〜約1:0.4 である、経口持続放出剤 形。 20.該キサンタンガムおよび該ローカストビーンガムの合計重量に対する該N SAIDの重量比が約0.08〜約0.25である、請求項19に記載の経口持続放出剤 形。 21.約 800〜約1000 mg のイブプロフェンを含む請求項19に記載の経口持続 放出錠剤。 22.キサンタンガム、ローカストビーンガム、不活性希釈剤および難溶性イブ プロフェンの混合物の湿式造粒を、キサンタンガムのローカストビーンガムに対 する比を約1:20〜約20:1とし、イブプロフェンの全重量の該キサンタンガムおよ び該ローカストビーンガムの合計重量に対する比を約1:0.06〜約1:0.4 として行 い;および得られた顆粒を、約 500〜約1000 mg のイブプロフェンを含む錠剤に 打錠する工程を含む、経口持続放出錠剤の製造法。 23.キサンタンガム、水溶液の存在下で該キサンタンガムを架橋し得るガラク トマンナン、および約20〜約35重量%の不活性希釈剤を含む、経口固体剤形で使 用するための持続放出薬剤賦形剤。 24.キサンタンガムおよびローカストビーンガムを含む持続放出マトリックス に約500 mg〜約1000 mg の難溶性NSAIDを含む持続放出錠剤であって、該錠 剤の合計重量が該難溶性NSAIDの約 110〜約 140重量%であり、該キサンタ ンガムおよび該ローカストビーンガムが錠剤の約 7〜約40重量%を含む持続放出 錠剤。 25.該NSAIDがイブプロフェンであり、該キサンタンガムおよび該ローカ ストビーンガムの合計重量がイブプロフェンの約 119〜約 136 %である、請求項 24に記載の持続放出錠剤。 26.キサンタンガムを含む持続放出イブプロフェン錠剤からのイブプロフェン の放出を、錠剤が水性環境に暴露されたときに遅らせる方法であって、該方法が 、持続放出イブプロフェン錠剤の約 5〜約95重量%のキサンタンガムを等量のロ ーカストビーンガムで置き換え、該キサンタンガムの該ローカストビーンガムに 対する比が約1:20〜約20:1の範囲であることを含む方法。 27.約 600〜約1000 mg のイブプロフェン;キサンタンガム;ローカストビー ンガム;および不活性希釈剤を含む持続放出イブプロフェン錠剤であって、該キ サンタンガムおよび該ローカストビーンガムの合計重量が最終の錠剤の重量の約 7〜約40重量%であり、該キサンタンガムおよび該ローカストビーンガムの合計 重量に対するイブプロフェンの比が約1:0.06〜約1:0.4 である持続放出イブプロ フェン錠剤。 28.該キサンタンガムおよび該ローカストビーンガムの合計重量に対するイブ プロフェンの比が約1:0.08〜約1:0.25である、請求項27に記載の持続放出イブ プロフェン錠剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2133596P | 1996-07-08 | 1996-07-08 | |
US60/021,335 | 1996-07-08 | ||
PCT/US1997/013331 WO1998001117A1 (en) | 1996-07-08 | 1997-07-08 | Sustained release matrix for high-dose insoluble drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10511407A true JPH10511407A (ja) | 1998-11-04 |
JP3148256B2 JP3148256B2 (ja) | 2001-03-19 |
Family
ID=21803631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50540898A Expired - Fee Related JP3148256B2 (ja) | 1996-07-08 | 1997-07-08 | 高用量難溶性薬物用持続放出マトリックス |
Country Status (12)
Country | Link |
---|---|
US (4) | US6093420A (ja) |
EP (1) | EP0859603B1 (ja) |
JP (1) | JP3148256B2 (ja) |
KR (1) | KR100321489B1 (ja) |
AT (1) | ATE417604T1 (ja) |
AU (1) | AU695734B2 (ja) |
CA (1) | CA2231195C (ja) |
DE (1) | DE69739165D1 (ja) |
ES (1) | ES2322405T3 (ja) |
IL (1) | IL123505A (ja) |
MX (1) | MX9801835A (ja) |
WO (1) | WO1998001117A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005037264A1 (ja) * | 2003-10-17 | 2005-04-28 | Medrx Co., Ltd. | ビグアナイド系薬剤を含有するゼリー製剤 |
JP2007505921A (ja) * | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
JP2009519326A (ja) * | 2005-12-16 | 2009-05-14 | ハンミ ファーム. シーオー., エルティーディー. | 低融点の活性成分を含む溶融状の固体分散体、及びこれを含む経口投与用錠剤 |
JP2009149691A (ja) * | 2001-03-13 | 2009-07-09 | Penwest Pharmaceuticals Co | 時間治療(chronotherapeutic)投与形態 |
JP2012515765A (ja) * | 2009-01-22 | 2012-07-12 | アボット ヘルスケア プライベート リミテッド | 時間治療用医薬組成物 |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US6726930B1 (en) * | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
JP3148256B2 (ja) * | 1996-07-08 | 2001-03-19 | エドワード メンデル カンパニー.,インコーポレーテッド | 高用量難溶性薬物用持続放出マトリックス |
EP1007049A1 (en) * | 1997-08-27 | 2000-06-14 | Hexal AG | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
US6056977A (en) | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
TR200002848T2 (tr) * | 1998-04-07 | 2001-02-21 | Alcon Laboratories, Inc. | Ksantan zamkı içeren, jelleşen oftalmik bileşimler. |
WO2000018374A1 (en) * | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
US8236352B2 (en) * | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE60038536T2 (de) * | 1999-09-30 | 2009-06-10 | Penwest Pharmaceuticals Co. | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
US20050037073A1 (en) * | 2000-01-13 | 2005-02-17 | Alpharx Inc. | Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof |
US7198795B2 (en) * | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
CN1610551A (zh) * | 2001-07-06 | 2005-04-27 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的肠胃外给药 |
US6705028B2 (en) * | 2001-09-12 | 2004-03-16 | Honda Giken Kogyo Kabushiki Kaisha | Self-propelled snowplow vehicle |
WO2003026743A2 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030152622A1 (en) * | 2001-10-25 | 2003-08-14 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral diuretic |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
CA2475092C (en) * | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
CA2479665C (en) * | 2002-03-20 | 2011-08-30 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
AU2003230805A1 (en) * | 2002-04-05 | 2003-10-27 | Penwest Pharmaceuticals Co. | Sustained release metoprolol formulations |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20030232097A1 (en) * | 2002-06-17 | 2003-12-18 | Strides Inc. | Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen |
US20040258757A1 (en) * | 2002-07-16 | 2004-12-23 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
EP1549296A4 (en) * | 2002-08-02 | 2006-08-09 | Penwest Pharmaceuticals Co | METFORMIN FORMULATIONS WITH DELAYED RELEASE |
RU2005133427A (ru) * | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | Безводные однофазные носители и препараты с использованием таких носителей |
US20050042289A1 (en) * | 2003-04-29 | 2005-02-24 | Yamanouchi Pharma Technologies, Inc. | Tablets and methods for modified release of hydrophylic and other active agents |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
US20050118267A1 (en) * | 2003-09-19 | 2005-06-02 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
US20070077297A1 (en) * | 2004-09-30 | 2007-04-05 | Scolr Pharma, Inc. | Modified release ibuprofen dosage form |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
CA2613403A1 (en) * | 2005-06-29 | 2007-01-04 | Panacea Biotec Ltd. | Modified release pharmaceutical compositions on the basis of two polymers and processes thereof |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
GB2438287A (en) * | 2006-05-19 | 2007-11-21 | Norbrook Lab Ltd | Stable aqueous suspension |
US7749537B2 (en) * | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
US9023381B2 (en) * | 2007-01-26 | 2015-05-05 | Michelle Chow | Enhanced medicinal delivery system processes and products thereby especially useful for children |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
PT2456424E (pt) | 2009-07-22 | 2013-09-30 | Gruenenthal Gmbh | Forma de dosagem resistente à adulteração e estabilizada contra a oxidação |
NZ596667A (en) | 2009-07-22 | 2013-09-27 | Gruenenthal Chemie | Hot-melt extruded controlled release dosage form |
CA2808541C (en) | 2010-09-02 | 2019-01-08 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
AU2013225106B2 (en) | 2012-02-28 | 2017-11-02 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9452135B2 (en) | 2012-03-20 | 2016-09-27 | Particle Dynamics International, Llc | Gelling agent-based dosage form |
RS57913B1 (sr) | 2012-04-18 | 2019-01-31 | Gruenenthal Gmbh | Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 1個または複数の粒子を含有する改変防止(tamper−resistant)剤形 |
JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
BR112016010482B1 (pt) | 2013-11-26 | 2022-11-16 | Grünenthal GmbH | Preparação de uma composição farmacêutica em pó por meio de criomoagem |
WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) * | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
EA035434B1 (ru) | 2015-04-24 | 2020-06-15 | Грюненталь Гмбх | Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN115666621A (zh) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | 具有减少的杂质的持续释放药物递送系统及相关方法 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670827C3 (de) * | 1967-03-20 | 1974-10-24 | Bayer Ag, 5090 Leverkusen | 4-(2'-Nitrophenyl)-2,6-dimethyl-3,5-dicarbmethoxy-1,4-dihydropyridin |
SU432703A3 (ja) * | 1971-08-24 | 1974-06-15 | Фридрих Боссерт, Вульф Фатер, Курт Бауер | |
DE2714065A1 (de) * | 1977-03-30 | 1978-10-12 | Boehringer Mannheim Gmbh | Instillationszubereitung |
GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
DE3033919A1 (de) * | 1980-09-09 | 1982-04-22 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung |
US4346709A (en) * | 1980-11-10 | 1982-08-31 | Alza Corporation | Drug delivery devices comprising erodible polymer and erosion rate modifier |
JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
JPS59101423A (ja) * | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | 新規なニフエジピン固形製剤 |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
DE3318649A1 (de) * | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | Zweiphasenformulierung |
DE3320582A1 (de) * | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
US4851229A (en) * | 1983-12-01 | 1989-07-25 | Alza Corporation | Composition comprising a therapeutic agent and a modulating agent |
JPS60139688A (ja) * | 1983-12-28 | 1985-07-24 | Tokyo Tanabe Co Ltd | 無定形ジヒドロピリジン粉末製剤 |
DE3400106A1 (de) * | 1984-01-04 | 1985-07-11 | Klaus-Dieter Dr. 3550 Marburg Bremecker | Pharmazeutische zubereitungen mit gesteuerter arzneistoff-freisetzung |
KR850700212A (ko) * | 1984-03-21 | 1985-12-26 | 죠지 드모트 | 서방성 약제학적 캼셀제 |
HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
DE3438830A1 (de) * | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
DE3586713T2 (de) * | 1984-11-15 | 1993-05-13 | Hercon Lab | Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen. |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
IT1187751B (it) * | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
IE63321B1 (en) * | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
GB8608818D0 (en) * | 1986-04-11 | 1986-05-14 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions |
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4803076A (en) * | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
DE3636123A1 (de) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten |
DE3682208D1 (de) * | 1986-12-18 | 1991-11-28 | Kurt Heinz Bauer | Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung. |
US5015479A (en) * | 1987-02-02 | 1991-05-14 | Seamus Mulligan | Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine |
GB8705083D0 (en) * | 1987-03-04 | 1987-04-08 | Euro Celtique Sa | Spheroids |
US5288500A (en) * | 1987-03-13 | 1994-02-22 | Benzon Pharma A/S | Oral composition containing particles comprising an active substance |
KR880012221A (ko) * | 1987-04-13 | 1988-11-26 | 사노 가즈오 | 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물 |
US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
FR2618073B1 (fr) * | 1987-07-16 | 1990-09-07 | Pf Medicament | Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation |
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4994276A (en) * | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
GB8722306D0 (en) * | 1987-09-22 | 1987-10-28 | Aps Research Ltd | Sustained-release formulation |
SE8703881D0 (sv) * | 1987-10-08 | 1987-10-08 | Haessle Ab | New pharmaceutical preparation |
GB8723896D0 (en) * | 1987-10-12 | 1987-11-18 | Aps Research Ltd | Controlled-release formulation |
US5160734A (en) * | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
JP2668730B2 (ja) * | 1988-03-09 | 1997-10-27 | 雪印乳業株式会社 | 天然ポリマーを用いた徐放性製剤 |
US5211957A (en) * | 1988-03-25 | 1993-05-18 | Ciba-Geigy Corporation | Solid rapidly disintegrating dosage form |
US5019397A (en) * | 1988-04-21 | 1991-05-28 | Alza Corporation | Aqueous emulsion for pharmaceutical dosage form |
JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
US5135757A (en) * | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5128143A (en) * | 1988-09-19 | 1992-07-07 | Edward Mendell Co., Inc. | Sustained release excipient and tablet formulation |
US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
HU203041B (en) * | 1989-03-14 | 1991-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5091190A (en) * | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US5024843A (en) * | 1989-09-05 | 1991-06-18 | Alza Corporation | Oral hypoglycemic glipizide granulation |
IE66933B1 (en) | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
IT1246188B (it) * | 1990-07-27 | 1994-11-16 | Resa Farma | Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute. |
GB9022788D0 (en) * | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
US5215758A (en) * | 1991-09-11 | 1993-06-01 | Euroceltique, S.A. | Controlled release matrix suppository for pharmaceuticals |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
US5273760A (en) * | 1991-12-24 | 1993-12-28 | Euroceltigue, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
GB9200607D0 (en) * | 1992-01-13 | 1992-03-11 | Ethical Pharma Ltd | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
IL104192A (en) * | 1992-02-17 | 1998-01-04 | Siegfried Ag Pharma | Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient |
US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
US5472711A (en) * | 1992-07-30 | 1995-12-05 | Edward Mendell Co., Inc. | Agglomerated hydrophilic complexes with multi-phasic release characteristics |
IT1255792B (it) * | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
US5324351A (en) * | 1992-08-13 | 1994-06-28 | Euroceltique | Aqueous dispersions of zein and preparation thereof |
US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
BE1006990A5 (nl) * | 1993-04-22 | 1995-02-07 | Univ Gent | Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen. |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
MX9704079A (es) * | 1994-12-01 | 1997-12-31 | Cibus Pharmaceutical Inc | Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores. |
JP3148256B2 (ja) * | 1996-07-08 | 2001-03-19 | エドワード メンデル カンパニー.,インコーポレーテッド | 高用量難溶性薬物用持続放出マトリックス |
US5845563A (en) * | 1997-01-10 | 1998-12-08 | Sunbeam Products, Inc. | Rotisserie cooker |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
-
1997
- 1997-07-08 JP JP50540898A patent/JP3148256B2/ja not_active Expired - Fee Related
- 1997-07-08 US US08/889,424 patent/US6093420A/en not_active Expired - Lifetime
- 1997-07-08 KR KR1019980701734A patent/KR100321489B1/ko not_active IP Right Cessation
- 1997-07-08 IL IL12350597A patent/IL123505A/en not_active IP Right Cessation
- 1997-07-08 DE DE69739165T patent/DE69739165D1/de not_active Expired - Lifetime
- 1997-07-08 ES ES97935184T patent/ES2322405T3/es not_active Expired - Lifetime
- 1997-07-08 MX MX9801835A patent/MX9801835A/es unknown
- 1997-07-08 AU AU38183/97A patent/AU695734B2/en not_active Ceased
- 1997-07-08 WO PCT/US1997/013331 patent/WO1998001117A1/en active IP Right Grant
- 1997-07-08 CA CA002231195A patent/CA2231195C/en not_active Expired - Fee Related
- 1997-07-08 EP EP97935184A patent/EP0859603B1/en not_active Expired - Lifetime
- 1997-07-08 AT AT97935184T patent/ATE417604T1/de not_active IP Right Cessation
-
1999
- 1999-10-19 US US09/420,247 patent/US6245355B1/en not_active Expired - Lifetime
-
2001
- 2001-04-25 US US09/842,289 patent/US6689386B2/en not_active Expired - Fee Related
-
2003
- 2003-12-09 US US10/731,859 patent/US20040121012A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009149691A (ja) * | 2001-03-13 | 2009-07-09 | Penwest Pharmaceuticals Co | 時間治療(chronotherapeutic)投与形態 |
JP2007505921A (ja) * | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
WO2005037264A1 (ja) * | 2003-10-17 | 2005-04-28 | Medrx Co., Ltd. | ビグアナイド系薬剤を含有するゼリー製剤 |
JP2009519326A (ja) * | 2005-12-16 | 2009-05-14 | ハンミ ファーム. シーオー., エルティーディー. | 低融点の活性成分を含む溶融状の固体分散体、及びこれを含む経口投与用錠剤 |
JP2012515765A (ja) * | 2009-01-22 | 2012-07-12 | アボット ヘルスケア プライベート リミテッド | 時間治療用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
US6689386B2 (en) | 2004-02-10 |
ES2322405T3 (es) | 2009-06-19 |
IL123505A0 (en) | 1998-10-30 |
AU695734B2 (en) | 1998-08-20 |
EP0859603A4 (en) | 2006-05-24 |
IL123505A (en) | 2004-12-15 |
CA2231195A1 (en) | 1998-01-15 |
KR100321489B1 (ko) | 2002-10-09 |
US6245355B1 (en) | 2001-06-12 |
AU3818397A (en) | 1998-02-02 |
ATE417604T1 (de) | 2009-01-15 |
US20040121012A1 (en) | 2004-06-24 |
US6093420A (en) | 2000-07-25 |
EP0859603A1 (en) | 1998-08-26 |
WO1998001117A1 (en) | 1998-01-15 |
CA2231195C (en) | 2003-01-21 |
DE69739165D1 (de) | 2009-01-29 |
EP0859603B1 (en) | 2008-12-17 |
JP3148256B2 (ja) | 2001-03-19 |
MX9801835A (es) | 1998-08-30 |
KR19990044486A (ko) | 1999-06-25 |
US20010021392A1 (en) | 2001-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3148256B2 (ja) | 高用量難溶性薬物用持続放出マトリックス | |
FI118001B (fi) | Kerran päivässä suun kautta otettava metoprololiannosmuoto | |
JP4077886B2 (ja) | 不溶性薬剤の持効性ヘテロ分散ヒドロゲル系 | |
US5811126A (en) | Controlled release matrix for pharmaceuticals | |
FI116450B (fi) | Menetelmä valmistaa metoprololin 24 tunnin valmistetta | |
JP3250737B2 (ja) | 放出制御製剤(アルブテロール) | |
KR100384215B1 (ko) | 방출지속성다분산하디로겔시스템-비정질약물 | |
FI113337B (fi) | Menetelmä pitkitetysti vapauttavan oksibutyniiniä sisältävän valmisteen valmistamiseksi | |
JPH01250314A (ja) | 徐放性製剤 | |
JPH0669965B2 (ja) | 固体持続放出医薬製剤 | |
JP5420590B2 (ja) | pH非依存延長放出性医薬組成物 | |
NO331689B1 (no) | Oral farmasoytisk sammensetning omfattende rivastigmin, samt anvendelse av rivastigmin | |
JP2003513882A (ja) | ジバルプロエックスナトリウムの制御放出製剤 | |
EP2405900A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
JP2774135B2 (ja) | 固体の急速に崩壊する剤形 | |
JPH0757726B2 (ja) | 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤 | |
JPS6087216A (ja) | 一定放出性固体投薬形インドメタシン組成物および関節炎その他の炎症性状態の治療法 | |
JPH08512061A (ja) | 持続放出性賦形剤 | |
MXPA94008792A (en) | Sustained release formulations for 24 hours of metopro release | |
NZ500677A (en) | Sustained release dosage form, comprising a non-steroidal anti-inflammatory agent, and a sustained release carrier which comprises xantham gum, locust bean gum and a diluent | |
MXPA96000024A (en) | Form of oral dosing of metoprolol one time |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090112 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090112 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100112 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110112 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120112 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130112 Year of fee payment: 12 |
|
LAPS | Cancellation because of no payment of annual fees |